glucaric acid has been researched along with Kidney Failure, Chronic in 76 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (9.21) | 18.2507 |
| 2000's | 45 (59.21) | 29.6817 |
| 2010's | 24 (31.58) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z | 1 |
| Batycky, A; Bernard, K; Dahl, NV; Li, Z; Macdougall, IC; Strauss, WE | 1 |
| Imai, N; Shibagaki, Y; Taki, Y | 1 |
| Coll, E; Corredor, ZF; Marcos, R; Pastor, S; Rodríguez-Ribera, L; Stoyanova, E | 1 |
| Münch, HG; Potthoff, SA | 1 |
| Mekic, M; Musanovic, A; Trnacevic, S | 1 |
| Airy, M; Brookhart, MA; Chang, TI; Ding, VY; Goldstein, BA; Mandayam, S; Mitani, AA; Winkelmayer, WC | 1 |
| Amato, C; Barbieri, C; Bellocchio, F; Bolzoni, E; Canaud, B; Cattinelli, I; Gatti, E; Macdougall, IC; Mari, F; Martin, JD; Stopper, A; Stuard, S | 1 |
| Cebrián, C; Deira, J; Fernández-Pereira, L; Gómez-Martino, JR; González-Sanchidrián, S; Jiménez, M; Marín, J; Polanco, S; Tabernero, J | 1 |
| Coyne, DW; Daloul, R; Pandey, R | 1 |
| Berger, SP; Daha, MR; de Vlaam, TP; Franssen, CF; Gaillard, CA; Gaya da Costa, M; Hempel, JC; Poppelaars, F; Seelen, MA | 1 |
| Airy, M; Brookhart, MA; Chang, TI; Ding, VY; Fishbane, S; Goldstein, BA; Mandayam, S; Mitani, AA; Winkelmayer, WC | 1 |
| Anirban, G; Gupta, KL; Jha, V; Kohli, HS; Sakhuja, V | 1 |
| Bailey, G; Cropper, L; Mostafa, S; Pugh-Clarke, K; Tagboto, S; Turner, J | 1 |
| Bolaños, L; González-Juanatey, C; Ranero, R; Testa, A | 1 |
| Collins, AJ; Foley, RN; Gilbertson, DT; Ibrahim, HN; Zhang, R | 1 |
| Lorch, JA; Pollak, VE; Satwah, S; Shukla, R | 1 |
| Bruguera, J; Cladellas, M; Comín-Colet, J; Rizzo, M; Ruiz, S; Torres, A | 1 |
| Andreoli, MC; Carneiro, FD; Espósito, BP; Guimarães-Souza, NK; Mallet, AC; Matos, AC; Rangel, EB; Santos, BF | 1 |
| Fernández-Gallego, J; Martín, MA; Sujan, S; Vega, E | 1 |
| Bhandari, S; Chinnappa, S | 1 |
| Hojs, N; Malovrh, M; Premru, V | 1 |
| Fenwick, S; Peebles, G | 1 |
| Atalay, H; Guney, I; Kaya, E; Solak, Y; Turk, S; Turkmen, K | 1 |
| Fujii, H; Fujimori, A; Fukagawa, M; Goto, S; Hasegawa, H; Komaba, H; Nishi, S; Nishioka, M; Takeda, Y; Umezu, M | 1 |
| Conner, TA; McQuade, C; Olp, J; Pai, AB | 1 |
| Gollapudi, S; Hassanzadeh, T; Ichii, H; Masuda, Y; Saffarian, M; Vaziri, ND | 1 |
| Bradbury, BD; Brookhart, MA; Freburger, JK; Kshirsagar, AV; Ng, LJ | 1 |
| Chen, J; Chen, X; Cheng, M; Peng, Y; Yang, L; Yin, L | 1 |
| Benmaadi, A; Bounhiol, C; Cohen, Y; Couprie, R; Dahan, H; Drahi, G; Griuncelli, M; Janklewicz, P; Loridon, C; Machado, G; Rostoker, G; Roy, M | 1 |
| Baruch, R; Blum, M; Iaina, A; Keren, G; Schwartz, D; Shaked, M; Sheps, D; Silverberg, DS; Steinbruch, S; Tchebiner, J; Wexler, D; Yachnin, T; Zubkov, A | 2 |
| Agarwal, R; Coyne, DW; Dahl, N; Folkert, VW; Michael, B; Myirski, P; Warnock, DG | 1 |
| Calişkan, S; Camsari, T; Cavdar, C; Celik, A; Onvural, B; Sifil, A; Temiz, A; Yeniçerioğlu, Y | 1 |
| Albarracín, C; Fanlo, B; Junquera, E; Rodríguez Palomares, JR | 1 |
| Cohen, G; Deicher, R; Hörl, WH; Müllner, M; Ziai, F | 1 |
| Avram, MM; Blaustein, DA; Chattopadhyay, J; Daoui, R; Gadh, R; Schwenk, MH; Singh, H | 1 |
| Folkert, VW | 1 |
| Blum, M; Iaina, A; Schwartz, D; Silverberg, D; Wexler, D | 1 |
| Aronoff, GR; Bennett, WM; Blumenthal, S; Charytan, C; Pennell, JP; Reed, J; Rothstein, M; Strom, J; Van Wyck, D; Wolfe, A; Yee, J | 1 |
| Bagdatoglu, O; Bali, M; Dhondt, AW; Guz, G; Kavutcu, M; Reis, KA; Sahinarslan, A; Sindel, S; Yalçin, R | 1 |
| Abe, R; Horiuchi, T; Ogi, M; Wakabayashi, M; Wakabayashi, T | 1 |
| El-Agroudy, A; El-Husseini, A; Hassan, N; Khalil, A; Sabry, A; Salem, A; Sheashaa, H; Sobh, M | 1 |
| Erturk, S; Keven, K; Kutlay, S; Nergizoglu, G | 1 |
| Collins, AJ; Obrador, GT; Roberts, TL; St Peter, WL | 1 |
| Barut, Y; Eres, M; Gürsu, RU; Murat, B; Ozdemir, A; Selamet, U; Yalinbaş, B | 1 |
| Hörl, WH; Sengölge, G; Sunder-Plassmann, G | 1 |
| Födinger, M; Hörl, WH; Mittermayer, F; Puttinger, H; Schaller, G; Scheiber-Mojdehkar, B; Sunder-Plassmann, G; Vychytil, A; Wolzt, M | 1 |
| Anbu, AT; Bradbury, MG; Kemp, T; O'donnell, K; Smith, PA | 1 |
| Agarwal, R | 2 |
| Raja, R; Rizkala, AR; Sirken, G | 1 |
| Boyd, AV; Harford, A; McQuade, CR; Norenberg, JP; Pai, AB; Zager, PG | 1 |
| Camps, J; Ferré, N; Joven, J; Mackness, B; Mackness, M; Marcas, L; Marsillach, J; Martínez-Vea, A | 1 |
| Das, J; George, P; Itty, C; Pawar, B | 1 |
| Deveci, M; Oymak, O; Sari, I; Sav, T; Sipahioglu, MH; Tokgoz, B; Utas, C | 1 |
| Vikrant, S | 1 |
| Charytan, C; Reed, J; Yee, J | 1 |
| Grzegorzewska, AE | 1 |
| Grekas, DM; Makedou, A; Makedou, K; Malindretos, P; Raptis, V; Rudenco, I; Sarafidis, PA | 1 |
| Li, H; Wang, SX | 1 |
| Blum, M; Frank, N; Iaina, A; Kaplan, E; Levi, BA; Peer, G; Silverberg, DS; Steinbruch, S | 1 |
| Blum, M; Iaina, A; Kaplan, E; Peer, G; Silverberg, DS | 1 |
| Hörl, WH; Sunder-Plassmann, G | 2 |
| Akcicek, F; Atabay, G; Basci, A; Celik, A; Cirit, M; Ok, E; Ozkahya, M; Toz, H; Unsal, A | 1 |
| Andrade, S; Colaço, S; Oliveira, C; Ponce, P; Santos, JP; Silva, J; Ventura, H | 1 |
| Claris, O; Picaud, JC; Putet, G; Salle, BL | 1 |
| Bailie, GR; Johnson, CA; Mason, NA | 1 |
| Descombes, E; Fellay, G | 1 |
| Grönhagen-Riska, C; Parkkinen, J; Peltonen, S; Rosenlöf, K; von Bonsdorff, L | 1 |
| Al-Saloum, M; Charytan, C; Gagnon, S; Hafeez, T; Levin, N; Van Wyck, DB | 1 |
| Agbaria, Z; Baruch, R; Blum, M; Deutsch, V; Iaina, A; Irony, M; Schwartz, D; Silverberg, DS; Steinbruch, S; Yachnin, T | 1 |
| Gosriwatana, I; Hider, RC; Kersting, S; Kooistra, MP; Lu, S; Marx, JJ; Nijhoff-Schutte, J | 1 |
| Eran, A; Harmankaya, O | 1 |
| Hanson, SY; Johnson, AC; Wasse, H; Zager, RA | 1 |
8 review(s) available for glucaric acid and Kidney Failure, Chronic
| Article | Year |
|---|---|
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, Physiological; Adipates; Administration, Oral; Adolescent; Adrenal Glands; Adsorption; Adult; Aged; Aged, 80 and over; Aging; AIDS-Related Opportunistic Infections; Aldosterone; Amino Acids; Ammonia; Amoxicillin; AMP-Activated Protein Kinases; Animals; Antacids; Anti-Bacterial Agents; Antineoplastic Agents; Antirheumatic Agents; Apgar Score; Area Under Curve; ARNTL Transcription Factors; Arterial Pressure; Arthritis, Juvenile; Athletes; Attention; Biodegradation, Environmental; Biofilms; Biofuels; Biological Therapy; Biomass; Biomimetic Materials; Bioreactors; Birth Weight; Bismuth; Blood Flow Velocity; Bone and Bones; Brain Injuries, Traumatic; Calcium; Calcium Channels; Capsaicin; Carbon; Carcinoma, Hepatocellular; Cardiomegaly, Exercise-Induced; Cartilage; Cartilage, Articular; Case-Control Studies; Catalysis; Cats; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Charcoal; Chemokine CCL2; Child; Child, Preschool; Chondrogenesis; Chronic Disease; Circadian Clocks; Circadian Rhythm Signaling Peptides and Proteins; Clarithromycin; Coccidioides; Coccidioidomycosis; Cognitive Behavioral Therapy; Coinfection; Color; Coloring Agents; Computer Simulation; Computers, Molecular; Consensus; Corticosterone; Cyclic AMP Response Element-Binding Protein; Cytochrome P-450 Enzyme System; Death, Sudden, Cardiac; Density Functional Theory; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dialysis Solutions; Disease Models, Animal; Dogs; Dopamine Agonists; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Electrocardiography; Electrocardiography, Ambulatory; Electrolytes; Endocardium; Endocrine Disruptors; Endocytosis; Endoscopy, Gastrointestinal; Escherichia coli Proteins; Esters; Evolution, Molecular; Executive Function; Feasibility Studies; Female; Ferric Compounds; Fluorescence; Fluorescent Dyes; Fluorine Radioisotopes; Frailty; Free Radical Scavengers; Gabapentin; Geriatric Assessment; Glucaric Acid; Glucocorticoids; Glucose; Glucose Metabolism Disorders; Halogenated Diphenyl Ethers; Heart Rate; Heart Ventricles; HEK293 Cells; Helicobacter Infections; Helicobacter pylori; Hep G2 Cells; Hepatocytes; Humans; Hungary; Hydrogen Sulfide; Hydrogen-Ion Concentration; Immunologic Factors; Immunomodulation; Immunosuppressive Agents; Independent Living; Indocyanine Green; Infant; Infant Formula; Infant Mortality; Infant, Newborn; Infant, Newborn, Diseases; Inflorescence; Insulin Resistance; Insulins; International Agencies; Iron; Isotonic Solutions; Kidney Failure, Chronic; Kinetics; Lactones; Leukocytes, Mononuclear; Liver Neoplasms; Macular Edema; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetosomes; Male; Medical Audit; Mesenchymal Stem Cells; Metabolic Syndrome; Metformin; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Middle Aged; Molecular Conformation; Molecular Targeted Therapy; Motor Activity; Multiple Sclerosis; Mycophenolic Acid; Netherlands; Neuropsychological Tests; Nuclear Energy; Organs at Risk; Osteoarthritis; Osteoarthritis, Hip; Oxidation-Reduction; Palladium; Pericardium; Perinatal Death; Peritoneal Dialysis; Phantoms, Imaging; Pharmaceutical Preparations; Phospholipids; Phosphorylation; Physical Conditioning, Human; Physical Endurance; Pilot Projects; Polyketides; Polymers; Positron-Emission Tomography; Postoperative Period; Potassium; Powders; Pramipexole; Predictive Value of Tests; Pregabalin; Pregnancy; Pregnancy Outcome; Protein Structure, Secondary; Proton Pump Inhibitors; Puberty; Pulmonary Circulation; Quality Assurance, Health Care; Quantum Dots; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Rats, Sprague-Dawley; Receptors, CCR2; Receptors, Transferrin; Regeneration; Registries; Renal Insufficiency, Chronic; Reproducibility of Results; Research Design; Restless Legs Syndrome; Retina; Retinoid X Receptor alpha; Retrospective Studies; Rhenium; Risk Factors; RNA, Messenger; Severity of Illness Index; Sex Factors; Sodium; Sodium Fluoride; Solvents; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Stereoisomerism; Stroke; Structure-Activity Relationship; Tachycardia, Ventricular; Tetracycline; Tetrahydrofolate Dehydrogenase; Tetrahydronaphthalenes; Thermodynamics; Thiophenes; Time Factors; Tinidazole; Tomography, Optical Coherence; Tomography, X-Ray Computed; Topiramate; Toxoplasma; Toxoplasmosis, Cerebral; Transferrin; Treatment Outcome; Up-Regulation; Upper Extremity; Uremia; Uveitis; Vascular Remodeling; Ventricular Fibrillation; Ventricular Function, Left; Ventricular Function, Right; Ventricular Remodeling; Verapamil; Veterans; Visual Acuity; Vitrectomy; Water Pollutants, Chemical; Zea mays; Zirconium | 2019 |
[Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease].
Topics: Administration, Oral; Anaphylaxis; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Humans; Infusions, Intravenous; Iron Compounds; Iron-Dextran Complex; Kidney Failure, Chronic; Maltose; Oxidative Stress; Renal Dialysis | 2013 |
Iron Treatment Strategies in Dialysis-Dependent CKD.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Ferrosoferric Oxide; Glucaric Acid; Hematinics; Hemoglobins; Humans; Iron Compounds; Iron-Dextran Complex; Kidney Failure, Chronic; Maltose; Renal Dialysis; Transferrin | 2016 |
Intravenous iron therapy: well-tolerated, yet not harmless.
Topics: Anemia; Cytokines; Endothelial Cells; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Gluconates; Hematinics; Humans; Injections, Intravenous; Iron; Iron-Dextran Complex; Kidney Failure, Chronic; Neutrophils | 2005 |
[Administration of iron-containing drugs in non-dialyzed patients with chronic kidney disease].
Topics: Administration, Oral; Anemia, Iron-Deficiency; Diet, Protein-Restricted; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Iron; Iron Metabolism Disorders; Iron, Dietary; Kidney Failure, Chronic; Risk Factors; Sex Distribution; Treatment Outcome | 2007 |
Safety aspects of parenteral iron in patients with end-stage renal disease.
Topics: Anemia, Iron-Deficiency; Citric Acid; Drug Combinations; Drug Monitoring; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Ferrous Compounds; Glucaric Acid; Humans; Infusions, Intravenous; Injections, Intravenous; Iron Compounds; Iron Overload; Iron-Dextran Complex; Kidney Failure, Chronic; Sorbitol | 1997 |
[Iron supplementation in preterm infants treated with erythropoietin].
Topics: Adult; Dietary Supplements; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infant, Newborn; Infant, Premature; Infusions, Intravenous; Kidney Failure, Chronic; Recombinant Proteins | 1999 |
Parenteral iron use in the management of anemia in end-stage renal disease patients.
Topics: Anemia, Iron-Deficiency; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Iron-Dextran Complex; Kidney Failure, Chronic; Peritoneal Dialysis; Recombinant Proteins; Renal Dialysis | 2000 |
29 trial(s) available for glucaric acid and Kidney Failure, Chronic
| Article | Year |
|---|---|
The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Heart; Hematinics; Humans; Kidney Failure, Chronic; Liver; Magnetic Resonance Imaging; Pancreas; Renal Dialysis | 2017 |
Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Biomarkers; C-Reactive Protein; Erythropoiesis; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hematinics; Hemoglobins; Hepcidins; Humans; Kidney Failure, Chronic; Maintenance Chemotherapy; Male; Renal Dialysis; Reticulocyte Count; Reticulocytes; Transferrin | 2016 |
The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
Topics: Adult; Age Factors; Analysis of Variance; Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Ferric Compounds; Ferric Oxide, Saccharated; Follow-Up Studies; Glucaric Acid; Humans; Infusions, Intravenous; Iron-Dextran Complex; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Predictive Value of Tests; Probability; Renal Dialysis; Risk Assessment; Severity of Illness Index; Sex Factors; Treatment Outcome | 2008 |
Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Cost-Benefit Analysis; Drug Administration Schedule; Drug Monitoring; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glomerular Filtration Rate; Glucaric Acid; Hemoglobins; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Severity of Illness Index; Sucrose; Transferrin; Treatment Outcome | 2008 |
Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose.
Topics: Adult; Ascorbic Acid; Cross-Over Studies; Cytokines; Epoetin Alfa; Erythropoietin; F2-Isoprostanes; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Lipid Peroxidation; Male; Membrane Potential, Mitochondrial; Middle Aged; Oxidative Stress; Prospective Studies; Reactive Oxygen Species; Recombinant Proteins; Systems Biology | 2012 |
[Multi-frequency low-dose intravenous iron on oxidative stress in maintenance hemodialysis patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress; Renal Dialysis; Sucrose; Young Adult | 2012 |
Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Biomarkers; Cross-Sectional Studies; Drug Therapy, Combination; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Hemosiderosis; Humans; Infusions, Intravenous; Iron; Kidney Failure, Chronic; Liver; Logistic Models; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Renal Dialysis | 2012 |
Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (> or =250 mg) administration.
Topics: Anemia, Iron-Deficiency; Drug Administration Schedule; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Population Surveillance; Treatment Outcome | 2003 |
The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
Topics: Adult; Dose-Response Relationship, Drug; Erythrocyte Deformability; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Injections, Intravenous; Iron; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress; Renal Dialysis; Sucrose; Time Factors | 2003 |
High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity.
Topics: Anemia; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Injections, Intravenous; Kidney Failure, Chronic; Neutrophils; Peritoneal Dialysis; Phagocytosis; Prospective Studies; Respiratory Burst | 2003 |
The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease.
Topics: Aged; Anemia; Blood Pressure; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Transferrin; Treatment Outcome | 2003 |
Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Drug Hypersensitivity; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Sepsis | 2004 |
Parenteral iron therapy in treatment of anemia in end-stage renal disease patients: a comparative study between iron saccharate and gluconate.
Topics: Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Gluconates; Humans; Kidney Failure, Chronic; Male; Parenteral Nutrition; Renal Dialysis | 2005 |
Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients.
Topics: Adult; Aged; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Forearm; Glucaric Acid; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress; Peritoneal Dialysis; Prospective Studies; Regional Blood Flow; Vasodilation | 2005 |
Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Topics: Biomarkers; Cross-Over Studies; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Iron-Dextran Complex; Kidney Failure, Chronic; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress; Prospective Studies; Renal Dialysis | 2007 |
Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
Topics: Aged; Anemia; Antibodies; Aryldialkylphosphatase; Dose-Response Relationship, Drug; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Injections, Intravenous; Injections, Subcutaneous; Kidney Failure, Chronic; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Recombinant Proteins; Renal Dialysis; Treatment Outcome | 2007 |
Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
Topics: Adult; Aged; Aged, 80 and over; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infusions, Intra-Arterial; Iron-Dextran Complex; Kidney Failure, Chronic; Male; Middle Aged | 2007 |
Optimum dosage regimen for iron sucrose.
Topics: Adult; Aged; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Kidney Failure, Chronic; Male; Middle Aged; Treatment Outcome | 2007 |
Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Biomarkers; C-Reactive Protein; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Inflammation Mediators; Infusions, Intravenous; Interleukin-6; Iron-Dextran Complex; Kidney Failure, Chronic; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Renal Dialysis; Serum Albumin; Tumor Necrosis Factor-alpha | 2007 |
Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Topics: Adult; Aged; Anemia; China; Drug Therapy, Combination; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferrous Compounds; Glucaric Acid; Hemoglobins; Humans; Iron; Kidney Failure, Chronic; Male; Middle Aged; Recombinant Proteins; Renal Dialysis; Treatment Outcome | 2008 |
Intravenous ferric saccharate as an iron supplement in dialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Drug Combinations; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Injections, Intravenous; Iron; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Prospective Studies; Renal Dialysis | 1996 |
Safety of intravenous injection of iron saccharate in haemodialysis patients.
Topics: Adult; Aged; Drug Tolerance; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Injections, Intravenous; Iron; Kidney Failure, Chronic; Kinetics; Male; Middle Aged; Recombinant Proteins; Renal Dialysis; Transferrin | 1996 |
The efficiency of fractionated parenteral iron treatment in CAPD patients.
Topics: Adult; Anemia; Drug Administration Schedule; Drug Therapy, Combination; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hematocrit; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Organization and Administration; Peritoneal Dialysis, Continuous Ambulatory; Recombinant Proteins; Sucrose; Transferrin | 1997 |
Iron supplementation in haemodialysis--practical clinical guidelines.
Topics: Anemia, Iron-Deficiency; Biomarkers; Drug Administration Routes; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Follow-Up Studies; Glucaric Acid; Hemoglobins; Humans; Iron; Iron Deficiencies; Kidney Failure, Chronic; Male; Middle Aged; Nutritional Support; Practice Guidelines as Topic; Prospective Studies; Recombinant Proteins; Renal Dialysis; Sucrose; Transferrin | 1998 |
Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration.
Topics: Adult; Aged; Bleomycin; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Injections, Intravenous; Iron; Kidney Failure, Chronic; Male; Middle Aged; Recombinant Proteins; Renal Dialysis; Staphylococcus epidermidis; Transferrin | 2000 |
Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.
Topics: Aged; Anemia, Iron-Deficiency; Epoetin Alfa; Erythrocyte Indices; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Injections, Intravenous; Iron; Kidney Failure, Chronic; Middle Aged; Prospective Studies; Recombinant Proteins; Renal Dialysis | 2001 |
The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Drug Therapy, Combination; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hematocrit; Humans; Infusions, Intravenous; Injections, Subcutaneous; Kidney Failure, Chronic; Male; Middle Aged; Recombinant Proteins; Renal Dialysis; Sucrose | 2001 |
Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion.
Topics: Anemia; Dialysis Solutions; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Infusions, Intravenous; Iron; Kidney Failure, Chronic; Male; Protein Binding; Renal Dialysis; Transferrin | 2002 |
Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin.
Topics: Aged; Anemia; Dose-Response Relationship, Drug; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Renal Dialysis | 2002 |
39 other study(ies) available for glucaric acid and Kidney Failure, Chronic
| Article | Year |
|---|---|
Zinc deficiency anaemia in haemodialysis patients: Often overlooked but a treatable cause of anaemia.
Topics: Aged, 80 and over; Anemia; Biomarkers; Carnosine; Darbepoetin alfa; Deficiency Diseases; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Hemoglobins; Humans; Kidney Failure, Chronic; Organometallic Compounds; Renal Dialysis; Treatment Outcome; Zinc; Zinc Compounds | 2017 |
Influence of Carnicor, Venofer, and Sevelamer on the levels of genotoxic damage in end-stage renal disease patients.
Topics: Carnitine; Chelating Agents; Comet Assay; DNA Damage; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Kidney Failure, Chronic; Lymphocytes; Male; Micronucleus Tests; Middle Aged; Neuroprotective Agents; Oxidative Stress; Sevelamer | 2018 |
The influence of inflammatory markers and CRP predictive value in relation to the target hemoglobin level in patients on chronic hemodialysis.
Topics: Aged; Anemia; Biomarkers; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Fibrinogen; Glucaric Acid; Hemoglobins; Humans; Inflammation; Kidney Failure, Chronic; Male; Middle Aged; Predictive Value of Tests; Renal Dialysis; ROC Curve; Sucrose | 2013 |
Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients.
Topics: Administration, Intravenous; Aged; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Hematinics; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Prognosis; Proportional Hazards Models; Renal Dialysis; Renal Insufficiency, Chronic; Stroke; United States | 2015 |
Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.
Topics: Aged; Anemia; Darbepoetin alfa; Disease Management; Erythropoiesis; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Hemoglobins; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Models, Statistical; Neural Networks, Computer; Renal Dialysis; Retrospective Studies | 2016 |
Distinct in vitro Complement Activation by Various Intravenous Iron Preparations.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Complement Activation; Complement C1q; Complement C3d; Complement Membrane Attack Complex; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Hematinics; Humans; In Vitro Techniques; Iron Compounds; Iron-Dextran Complex; Kidney Failure, Chronic; Maltose; Mannose-Binding Lectin; Properdin; Renal Dialysis | 2017 |
Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.
Topics: Administration, Intravenous; Aged; Anemia; Cardiovascular Diseases; Cause of Death; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infections; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Proportional Hazards Models; Renal Dialysis; Retrospective Studies | 2017 |
Intravenous iron sucrose does not impair sonographic brachial vasodilation in peritoneal dialysis patients.
Topics: Brachial Artery; Endothelium, Vascular; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Ultrasonography; Vasodilation | 2008 |
Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients.
Topics: Aged; Anemia, Iron-Deficiency; Centers for Medicare and Medicaid Services, U.S.; Drug Therapy, Combination; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Hemoglobins; Humans; Injections, Intravenous; Iron-Dextran Complex; Kidney Failure, Chronic; Male; Middle Aged; Odds Ratio; Practice Guidelines as Topic; Renal Dialysis; Retrospective Studies; Risk Assessment; Time Factors; Treatment Outcome; United States | 2009 |
The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Topics: Adult; Aged; Anemia; Comorbidity; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hemoglobins; Humans; Infusions, Intravenous; Iron-Dextran Complex; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Renal Dialysis; Retrospective Studies; Survival Analysis; Transferrin | 2009 |
A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical ou
Topics: Aged; Aged, 80 and over; Anemia; Chronic Disease; Cohort Studies; Drug Evaluation; Drug Therapy, Combination; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Follow-Up Studies; Glucaric Acid; Heart Failure; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Neurotransmitter Agents; Pilot Projects; Prospective Studies; Recombinant Proteins; Survival Rate; Syndrome; Time Factors; Treatment Outcome | 2009 |
Labile plasma iron generation after intravenous iron is time-dependent and transitory in patients undergoing chronic hemodialysis.
Topics: Aged; Aged, 80 and over; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infusions, Intravenous; Iron; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Time Factors | 2010 |
[Treatment with intravenous iron and ferritin level].
Topics: Anemia; Blood Proteins; Case-Control Studies; Clinical Protocols; Drug Monitoring; Erythropoiesis; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Oxidation-Reduction; Prospective Studies; Renal Dialysis | 2010 |
Influence of intravenous iron therapy on novel markers of iron deficiency.
Topics: Anemia, Iron-Deficiency; Biomarkers; Cross-Sectional Studies; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hematinics; Hemoglobins; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Renal Dialysis; Reticulocytes; Time Factors; Transferrin; Treatment Outcome | 2010 |
The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hematinics; Hemoglobins; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis | 2011 |
Total dose infusion of intravenous iron in patients with chronic kidney disease receiving haemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Middle Aged; Renal Dialysis; Young Adult | 2011 |
Comparison of adverse-event profiles of intravenous low-molecular-weight iron dextran and iron sucrose in peritoneal dialysis patients.
Topics: Adult; Aged; Anemia; Dextrans; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis | 2011 |
Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients.
Topics: Aged; Female; Ferric Compounds; Ferric Oxide, Saccharated; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Glands; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Vitamin D | 2011 |
Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes.
Topics: Adult; Anemia; Apoptosis; Carbohydrates; Escherichia coli; Female; Ferric Compounds; Ferric Oxide, Saccharated; Flow Cytometry; Glucaric Acid; Hematinics; Humans; Kidney Failure, Chronic; Male; Neutrophils; Phagocytosis; Staphylococcus aureus; Time Factors | 2012 |
Changing patterns of anemia management in US hemodialysis patients.
Topics: Adolescent; Adult; Aged; Anemia; Child; Child, Preschool; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Hemoglobins; Humans; Infusions, Intravenous; Iron Compounds; Kidney Failure, Chronic; Male; Middle Aged; Practice Patterns, Physicians'; Renal Dialysis; Time Factors; United States | 2012 |
The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization.
Topics: Aged; Anemia; Disease Progression; Drug Therapy, Combination; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Heart Failure; Hospitalization; Humans; Injections, Intravenous; Injections, Subcutaneous; Kidney Failure, Chronic; Male; Oxygen Consumption; Recombinant Proteins; Stroke Volume | 2002 |
[Changes in iron metabolism and erythropoietin requirements after the switch from ferric gluconate to iron saccharose. Is it worth the increased expense?].
Topics: Aged; Aged, 80 and over; Anemia; Cost-Benefit Analysis; Drug Costs; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Iron; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Spain; Sucrose | 2003 |
Intravenous iron therapy in chronic kidney disease and peritoneal dialysis patients.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infusions, Intravenous; Iron; Iron-Dextran Complex; Kidney Failure, Chronic; Peritoneal Dialysis | 2003 |
The use of androgens in anaemia resistant to erythropoietin and i.v. iron in patients with heart and renal failure.
Topics: Aged; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Heart Failure; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Nandrolone; Nandrolone Decanoate; Sucrose | 2004 |
Elevated cardiac troponin T in hemodialysis patients receiving more intravenous iron sucrose.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Biomarkers; Blood Chemical Analysis; Case-Control Studies; Chi-Square Distribution; Combined Modality Therapy; Coronary Artery Disease; Disease Progression; Dose-Response Relationship, Drug; Female; Ferric Compounds; Ferric Oxide, Saccharated; Follow-Up Studies; Glucaric Acid; Humans; Incidence; Infusions, Intravenous; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Reference Values; Renal Dialysis; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Sex Distribution; Statistics, Nonparametric; Survival Rate; Treatment Outcome; Troponin T | 2004 |
[Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients].
Topics: Aged; Anemia, Iron-Deficiency; Ascorbic Acid; Biomarkers; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Iron; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Retrospective Studies; Treatment Outcome | 2004 |
Combination of intravenous iron sucrose and ascorbic acid in hemodialysis patients.
Topics: Anemia; Antioxidants; Ascorbic Acid; Drug Therapy, Combination; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Injections, Intravenous; Kidney Failure, Chronic; Renal Dialysis | 2005 |
Trends in intravenous iron use among dialysis patients in the United States (1994-2002).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hypochromic; Child; Child, Preschool; Drug Utilization; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Incidence; Infant; Infusions, Intravenous; Kidney Failure, Chronic; Male; Medicare; Middle Aged; Outpatients; Peritoneal Dialysis; Prevalence; Recombinant Proteins; Renal Dialysis; Retrospective Studies; United States | 2005 |
Relationship between iron replacement and hepatic functions in hepatitis C virus-positive chronic haemodialysis patients.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Injections, Intravenous; Kidney Failure, Chronic; Liver; Male; Middle Aged; Renal Dialysis; Retrospective Studies | 2005 |
Low incidence of adverse events following 90-minute and 3-minute infusions of intravenous iron sucrose in children on erythropoietin.
Topics: Anemia; Child; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Prospective Studies; Recombinant Proteins | 2005 |
Proinflammatory effects of iron sucrose in chronic kidney disease.
Topics: Aged; Chemokine CCL2; Chronic Disease; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Inflammation; Kidney Diseases; Kidney Failure, Chronic; Reproducibility of Results | 2006 |
Is i.v. iron really superior in CKD patients not on dialysis?
Topics: Administration, Oral; Dose-Response Relationship, Drug; Ferric Compounds; Ferric Oxide, Saccharated; Follow-Up Studies; Glucaric Acid; Humans; Hypotension; Injections, Intravenous; Kidney Failure, Chronic; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2006 |
Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients.
Topics: Aged; Anemia, Iron-Deficiency; Bacteremia; Chi-Square Distribution; Dose-Response Relationship, Drug; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Poisson Distribution; Renal Dialysis; Retrospective Studies; Risk Assessment; Risk Factors; Statistics, Nonparametric | 2006 |
Coronary artery vasospasm with iron sucrose.
Topics: Coronary Vasospasm; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Middle Aged; Myocardial Ischemia | 2007 |
The safety of intravenous iron sucrose use in the elderly patient.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Geriatrics; Glucaric Acid; Hematinics; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis | 2007 |
Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.
Topics: Administration, Oral; Adult; Aged; Anemia; Anemia, Iron-Deficiency; Delayed-Action Preparations; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferrous Compounds; Follow-Up Studies; Glucaric Acid; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Time Factors | 1996 |
Improved response to erythropoietin therapy with long-term continuous iron supplementation.
Topics: Anemia, Iron-Deficiency; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hemoglobins; Humans; Iron; Iron Overload; Kidney Failure, Chronic; Male; Middle Aged; Recombinant Proteins; Renal Dialysis | 2000 |
Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases.
Topics: Aged; Anemia; Disease Progression; Drug Therapy, Combination; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glomerular Filtration Rate; Glucaric Acid; Heart Failure; Humans; Kidney Failure, Chronic; Male; Recombinant Proteins; Stroke Volume; Sucrose | 2001 |
Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury.
Topics: Animals; Aorta; Cell Division; Cell Line; Cell Line, Transformed; Cell Survival; Chlorides; Endothelium, Vascular; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Iron; Iron-Dextran Complex; Kidney Failure, Chronic; Kidney Tubules, Proximal; Lipid Peroxidation; Male; Malondialdehyde; Mice; Oligosaccharides; Oxidants; Parenteral Nutrition | 2002 |